Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed. The honeysuckle extract is used in combination with the antibiotics, the responsiveness of multi-drug resistant bacteria to antibiotics is improved, a clinical application prospect is presented, especially the current status of the refractory bacterial infection diseases caused by the pathogenic bacteria resistant to the antibiotics can be improved. Also provided is a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for prevention and/or treatment a diseases caused by bacteria. In addition, also provided is a use of the honeysuckle extract in the preparation of drugs for reversing bacterial resistance.

The present invention relates to use of a composition in the manufacture of a health care product or medicament for preventing and treating leucopenia induced by radiotherapy or chemotherapy. The composition is made from raw materials comprising 5 to 200 parts by weight of Ganoderma, 5 to 150 parts by weight of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts by weight of fermented Cordyceps sinensis powder and/or 1 to 120 parts by weight of Cordyceps, or is a composition consisting of water and/or alcohol extracts of the above raw materials as active components.

The present invention relates to use of a composition in the manufacture of a health care product or medicament for preventing and treating leucopenia induced by radiotherapy or chemotherapy. The composition is made from raw materials comprising 5 to 200 parts by weight of Ganoderma, 5 to 150 parts by weight of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts by weight of fermented Cordyceps sinensis powder and/or 1 to 120 parts by weight of Cordyceps, or is a composition consisting of water and/or alcohol extracts of the above raw materials as active components.

The present invention relates to use of a composition in the manufacture of a health care product or medicament for preventing and treating leucopenia induced by radiotherapy or chemotherapy. The composition is made from raw materials comprising 5 to 200 parts by weight of Ganoderma, 5 to 150 parts by weight of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts by weight of fermented Cordyceps sinensis powder and/or 1 to 120 parts by weight of Cordyceps, or is a composition consisting of water and/or alcohol extracts of the above raw materials as active components.

The invention provides a composition including a succulent extract and an alginic acid component consisting of alginic acid and/or one or more salts thereof, wherein the succulent extract is present in an amount in a range from 0.1 wt % to 1000 wt % relative to the alginic acid component, both on a dry basis.

The invention provides a composition including a succulent extract and an alginic acid component consisting of alginic acid and/or one or more salts thereof, wherein the succulent extract is present in an amount in a range from 0.1 wt % to 1000 wt % relative to the alginic acid component, both on a dry basis.

Disclosed are a method for preparing a hydroalcoholic extract obtained from a biomass of the shoots of a plant from the family of Plumbaginaceae, a butanol extract of Armenia maritima, a method for the preparation thereof, the use thereof, and compositions containing same.

The group of inventions provides a biologically active additive and a method for preparing same. The biologically active additive is a micellar solution of an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, the emulsifier being adsorbed on amorphous mesoporous silicon dioxide nanoparticles having mesopore size from 0.2 to 1.8 nm by way of stirring in a disperser. The active substance may be selected from the group comprising: curcumin extract and rutin extract, dihydroquercetin extract, dihydroquercetin extract with quercetin extract, mixed tocopherol concentrate, cannabis oil with cannabidiol level up to 85%, cannabidiol isolate, cannabidiol isolate with mixed tocopherol concentrate, ADEK vitamin mixture concentrate, Sophora japonica extract, rosemary extract, cholecalciferol, thioctic acid, ferulic acid, resveratrol, resveratrol with ferulic acid, boswellia extract, betulin extract, icariin extract, chlorophyll extract, cannabidiol isolate with melatonin, cannabis oil having cannabidiol level up to 85% with passionflower extract, vardenafil, tadalafil, curcumin extract with soy lecithin, paclitaxel extract, collagen extract with soy lecithin. A method for preparing a biologically active additive comprises loading, into the disperser, an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, heating to a temperature of 80-90° C. while stirring continuously at from about 1000 rpm to about 2000 rpm, cooling to a temperature from below 60° C. to below 45° C., adding amorphous mesoporous silicon dioxide having a mesopore size from 0.2 to 1.8 nm, stirring at from about 1000 rpm to about 2000 rpm for about 0.5 h, followed by an increase in the stirring speed to 7000-9000 rpm until producing a homogeneous product in the form of a loose powder. The group of inventions provides improved bioavailability of the active substance.

The group of inventions provides a biologically active additive and a method for preparing same. The biologically active additive is a micellar solution of an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, the emulsifier being adsorbed on amorphous mesoporous silicon dioxide nanoparticles having mesopore size from 0.2 to 1.8 nm by way of stirring in a disperser. The active substance may be selected from the group comprising: curcumin extract and rutin extract, dihydroquercetin extract, dihydroquercetin extract with quercetin extract, mixed tocopherol concentrate, cannabis oil with cannabidiol level up to 85%, cannabidiol isolate, cannabidiol isolate with mixed tocopherol concentrate, ADEK vitamin mixture concentrate, Sophora japonica extract, rosemary extract, cholecalciferol, thioctic acid, ferulic acid, resveratrol, resveratrol with ferulic acid, boswellia extract, betulin extract, icariin extract, chlorophyll extract, cannabidiol isolate with melatonin, cannabis oil having cannabidiol level up to 85% with passionflower extract, vardenafil, tadalafil, curcumin extract with soy lecithin, paclitaxel extract, collagen extract with soy lecithin. A method for preparing a biologically active additive comprises loading, into the disperser, an active substance in at least one emulsifier selected from the group comprising: polysorbate 20, polysorbate 80, polysorbate 20 and polysorbate 80, heating to a temperature of 80-90° C. while stirring continuously at from about 1000 rpm to about 2000 rpm, cooling to a temperature from below 60° C. to below 45° C., adding amorphous mesoporous silicon dioxide having a mesopore size from 0.2 to 1.8 nm, stirring at from about 1000 rpm to about 2000 rpm for about 0.5 h, followed by an increase in the stirring speed to 7000-9000 rpm until producing a homogeneous product in the form of a loose powder. The group of inventions provides improved bioavailability of the active substance.

The invention discloses a novel anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine extracted from Sesuvium portulacastrum (S. portulacastrum) having the structure as represented by Formula (I). The invention also discloses a method of extraction of this anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine from S. portulacastrum. The invention further relates to characterization of the anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine and study of its effect on the cancer cell cycle progression and expression of genes involved in apoptosis.

##STR00001##